Interpace Biosciences, Inc. (IDXG)
OTCMKTS
· Delayed Price · Currency is USD
2.650
-0.250 (-8.62%)
Dec 27, 2024, 4:00 PM EST
Interpace Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 44.89 | 40.21 | 31.84 | 33.12 | 32.4 | 24.22 | Upgrade
|
| Revenue Growth (YoY) | 17.33% | 26.31% | -3.86% | 2.22% | 33.77% | 10.61% | Upgrade
|
| Cost of Revenue | 17.75 | 16.31 | 13.61 | 14.31 | 21.67 | 15.89 | Upgrade
|
| Gross Profit | 27.14 | 23.9 | 18.23 | 18.8 | 10.73 | 8.33 | Upgrade
|
| Selling, General & Admin | 20.13 | 19.6 | 20.1 | 19.88 | 27.45 | 25.48 | Upgrade
|
| Research & Development | 0.64 | 0.64 | 0.7 | 1.49 | 2.8 | 2.81 | Upgrade
|
| Operating Expenses | 20.79 | 21.09 | 22.07 | 24.57 | 34.7 | 32.28 | Upgrade
|
| Operating Income | 6.36 | 2.81 | -3.84 | -5.76 | -23.98 | -23.95 | Upgrade
|
| Interest Expense | -0.78 | -1.01 | -1.01 | -1.04 | -0.55 | -0.44 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.67 | -0.67 | -1.21 | -0.38 | 0.47 | 0.2 | Upgrade
|
| EBT Excluding Unusual Items | 4.91 | 1.14 | -6.06 | -7.18 | -24.06 | -24.19 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -0.9 | -2.58 | -2.53 | Upgrade
|
| Other Unusual Items | -0.01 | -0.01 | 0.22 | 0.34 | 0.49 | 0.04 | Upgrade
|
| Pretax Income | 4.9 | 1.13 | -5.84 | -7.74 | -26.15 | -26.68 | Upgrade
|
| Income Tax Expense | 0.02 | 0.02 | 0.03 | -0.71 | 0.05 | -0.03 | Upgrade
|
| Earnings From Continuing Operations | 4.89 | 1.11 | -5.87 | -7.04 | -26.2 | -26.65 | Upgrade
|
| Earnings From Discontinued Operations | -0.19 | -0.31 | -16.09 | -7.91 | -0.25 | -0.09 | Upgrade
|
| Net Income | 4.7 | 0.8 | -21.96 | -14.94 | -26.45 | -26.74 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 3.03 | 0.43 | Upgrade
|
| Net Income to Common | 4.7 | 0.8 | -21.96 | -14.94 | -29.48 | -27.17 | Upgrade
|
| Shares Outstanding (Basic) | 4 | 4 | 4 | 4 | 4 | 4 | Upgrade
|
| Shares Outstanding (Diluted) | 4 | 4 | 4 | 4 | 4 | 4 | Upgrade
|
| Shares Change (YoY) | 2.28% | 2.97% | 2.49% | 2.63% | 7.55% | 33.03% | Upgrade
|
| EPS (Basic) | 1.08 | 0.19 | -5.18 | -3.61 | -7.32 | -7.25 | Upgrade
|
| EPS (Diluted) | 1.07 | 0.18 | -5.18 | -3.61 | -7.32 | -7.25 | Upgrade
|
| Free Cash Flow | 3.71 | 3.32 | -8.01 | -9.07 | -15.55 | -19.09 | Upgrade
|
| Free Cash Flow Per Share | 0.84 | 0.76 | -1.89 | -2.19 | -3.86 | -5.10 | Upgrade
|
| Gross Margin | 60.46% | 59.44% | 57.26% | 56.78% | 33.10% | 34.40% | Upgrade
|
| Operating Margin | 14.16% | 6.99% | -12.06% | -17.40% | -74.01% | -98.87% | Upgrade
|
| Profit Margin | 10.47% | 1.99% | -68.97% | -45.12% | -91.01% | -112.18% | Upgrade
|
| Free Cash Flow Margin | 8.27% | 8.25% | -25.17% | -27.40% | -48.01% | -78.81% | Upgrade
|
| EBITDA | 6.63 | 3.84 | -1.28 | -0.39 | -18.48 | -19.42 | Upgrade
|
| EBITDA Margin | 14.78% | 9.54% | -4.02% | -1.18% | -57.03% | -80.19% | Upgrade
|
| D&A For EBITDA | 0.28 | 1.03 | 2.56 | 5.37 | 5.5 | 4.52 | Upgrade
|
| EBIT | 6.36 | 2.81 | -3.84 | -5.76 | -23.98 | -23.95 | Upgrade
|
| EBIT Margin | 14.16% | 6.99% | -12.06% | -17.40% | -74.01% | -98.87% | Upgrade
|
| Effective Tax Rate | 0.35% | 1.51% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.